Jorge Ruas

Jorge Ruas

Professor
E-postadress: jorge.ruas@ki.se
Telefon: +46852487261
Besöksadress: Solnavägen 9, Biomedicum C5, 17165 Solna
Postadress: C3 Fysiologi och farmakologi, C3 FyFa Molekylär och cellulär arbetsfysiologi, 171 77 Stockholm

Om mig

  • Professor och forskargruppsledare för Molekylär och cellulär arbetsfysiologi vid institutionen för fysiologi och farmakologi.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Regulation of Adipose Tissue Function by Neuroendocrine Communication
    Novo Nordisk Foundation
    1 October 2023 - 30 September 2024
  • Um outro olhar para a prescrição do exercício: Exercício a diferentes horas do dia e o ciclo circadiano em pessoas com diabetes tipo 2 e aqueles que se encontram em risco
    Fundação para a Ciência e Tecnologia
    1 March 2023 - 28 February 2025
  • Swedish Research Council
    1 January 2023 - 31 December 2026
    Nonalcoholic fatty liver disease (NAFLD) is estimated to affect up to one third of the adult population in industrialized countries and 70-80% of obese patients with diabetes. The milder stage, hepatic steatosis, is often asymptomatic and undiagnosed but over 30% of these patients progress to nonalcoholic steatohepatitis (NASH). NASH impairs liver function and is a risk factor for cirrhosis, hepatocellular carcinoma, and cardiovascular disease. Amongst obese patients with diabetes, 30-50% develop NASH. There are no specific pharmacological treatments for NASH and drug development depends on a better understanding of the mechanisms underlying its pathogenesis. In addition, there are no biomarkers to diagnose and monitor NAFLD/NASH progression.We have identified a protein with previously unknown function and discovered that it operates as a major regulator of inflammation, extracellular matrix remodeling, and fibrogenesis. Based on its function, we have named it Tissue Remodeler and Activator of INflammation (TRAIN). TRAIN expression is elevated in human and rodent liver disease. We have observed that increasing TRAIN expression in mouse liver is sufficient to elicit many of the metabolic, morphological, histological, and transcriptional abnormalities characteristic of NASH. Our goal is to understand how TRAIN activation leads to NALFD/NASH, to identify reliable disease biomarkers and to develop novel therapies for NAFLD/NASH by manipulating TRAIN activity.
  • Regulation of Adipose Tissue Neuroendocrine Communication by Kynurenine Metabolites
    Novo Nordisk Foundation
    1 October 2021 - 30 September 2023
  • T.R.A.I.N., a novel target in Non-Alcoholic Fatty Liver Disease (NAFLD): Disease Mechanisms, Biomarkers, and Therapeutics.
    Novo Nordisk Foundation
    1 July 2019 - 30 June 2024
  • Research Institute for Medicines
    Fundação para a Ciência e Tecnologia
    1 January 2019 - 31 December 2019
  • PGC-1alpha Isoforms as novel Therapeutic targets in ParkinsON's Disease
    Fundação para a Ciência e Tecnologia
    1 August 2018 - 31 July 2022
  • Molecular Mechanisms Regulating Skeletal Muscle Function and their Systemic Impact
    Novo Nordisk Foundation
    1 January 2017 - 1 January 2020
  • Swedish Research Council
    1 January 2017 - 31 December 2022
  • Swedish Research Council
    1 January 2015 - 31 December 2018
  • Modeling information flow between tissues during metabolic adaptation and dysfunction
    International Human Frontier Science Program Organization
    1 May 2014 - 30 April 2017
  • Mechanisms of Skeletal Muscle Adaptations to Exercise
    Novo Nordisk Foundation
    19 March 2012 - 18 March 2017
  • MECHANISM OF HYPOXIA DEPENDENT TRANSCRIPTION ACTIVATION MEDIATED BY THE HYPOXIA-INDUCIBLE FACTOR-1
    Fundação para a Ciência e Tecnologia
    1 July 1999 - 30 June 2003
  • STUDY OF THE POLYMORPHISM OF THE CYP2AG AND CYP2C19 GENES IN PORTUGUESE POPULATIONS.
    Fundação para a Ciência e Tecnologia
    1 August 1996 - 31 July 1998

Anställningar

  • Professor, Fysiologi och farmakologi, Karolinska Institutet, 2020-

Examina och utbildning

  • Docent, Molekylär fysiologi, Karolinska Institutet, 2016
  • MEDICINE DOKTORSEXAMEN, Institutionen för cell- och molekylärbiologi, Karolinska Institutet, 2005
  • Pharm.D., Pharmaceutical Sciences, University of Lisbon, 1995

Gästforskning och resestipendier

  • Postdoc, Harvard Medical School, Postdoc in Molecular Muscle Physiology, 2006-2011

Nyheter från KI

Kalenderhändelser från KI